Aclaris Therapeutics, Inc. — Director's Dealing 2015

Oct 7, 2015

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Aclaris Therapeutics, Inc. (ACRS)
CIK: 0001557746
Period of Report: 2015-10-06

Reporting Person: Tullman Stephen A. (Director)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	347826	Indirect
Common Stock	521739	Indirect

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series A Preferred Stock	$		Common Stock (31884)		Indirect
Series B Preferred Stock	$		Common Stock (9250)		Indirect
Series C Preferred Stock	$		Common Stock (5054)		Indirect
Stock Option (right to buy)	$0.72	2024-08-12	Common Stock (19283)		Direct
Stock Option (right to buy)	$1.52	2024-12-07	Common Stock (43478)		Direct
Stock Option (right to buy)	$10.66	2025-08-31	Common Stock (22180)		Direct

Footnotes

F1: These shares are held by the 2007 Irrevocable Trust of Stephen A. Tullman, for which Mr. Tullman's spouse serves as the trustee.

F2: These shares are held by NeXeption, LLC, of which Mr. Tullman is the Manager.

F3: Each share of the Series A Preferred Stock is convertible, at any time, at the holder's election, into 0.289855 shares of the Issuer's common stock. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A Preferred Stock will automatically convert into 0.289855 shares of the Issuer's common stock. The Series A Preferred Stock has no expiration date.

F4: Each share of the Series B Preferred Stock is convertible, at any time, at the holder's election, into 0.289855 shares of the Issuer's common stock. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series B Preferred Stock will automatically convert into 0.289855 shares of the Issuer's common stock. The Series B Preferred Stock has no expiration date.

F5: Each share of the Series C Preferred Stock is convertible, at any time, at the holder's election, into 0.289855 shares of the Issuer's common stock. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series C Preferred Stock will automatically convert into 0.289855 shares of the Issuer's common stock. The Series C Preferred Stock has no expiration date.

F6: 25% of the shares underlying this option vested on August 13, 2015 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date.

F7: 25% of the shares underlying this option will vest on December 8, 2015 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date.

F8: 25% of the shares underlying this option will vest on September 1, 2016 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the Issuer as of the applicable vesting date.